Methyl2-(1-isopropyl-1H-1,2,3-triazol-4-yl)acetate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Methyl2-(1-isopropyl-1H-1,2,3-triazol-4-yl)acetate
• 英文别名: methyl 2-(1-propan-2-yltriazol-4-yl)acetate
• 化学式: C₈H₁₃N₃O₂
• 分子量: 183.21
• InChiKey: XIOJHGNJIPJEIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  57
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES
  申请人：Akebia Therapeutics, Inc.

  公开号：US20210122715A1

  公开（公告）日：2021-04-29

  Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]-alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5-heteroaryl substituted [(3-hydroxypyridine-2-carbonyl]amino}acetic acids. Further disclosed are methods for making prodrugs of [(3-hydroxypyridine-2-carbonyl)-amino]acetic acids, for example, [(3-hydroxypyridine-2-carbonyl]amino}acetic acid esters and [3-hydroxypyridine-2-carbonyl]amino}acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibitors or for treating conditions wherein prolyl hydroxylase inhibition is desired.

  本发明涉及制备[(3-羟基吡啶-2-羧基)氨基]-烷基酸，其衍生物，包括5-芳基取代和5-杂环芳基取代的[(3-羟基吡啶-2-羧基)氨基]乙酸。此外，本发明还公开了制备[(3-羟基吡啶-2-羧基)氨基]乙酸前药的方法，例如[(3-羟基吡啶-2-羧基)氨基]乙酸酯和[3-羟基吡啶-2-羧基)氨基]乙酸酰胺。所公开的化合物可用作脯氨酸羟化酶抑制剂或用于治疗需要脯氨酸羟化酶抑制的疾病的药物。
• Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
  申请人：Akebia Therapeutics, Inc.

  公开号：US11267785B2

  公开（公告）日：2022-03-08

  Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]-alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5-heteroaryl substituted [(3-hydroxypyridine-2-carbonyl]amino}acetic acids. Further disclosed are methods for making prodrugs of [(3-hydroxypyridine-2-carbonyl)-amino]acetic acids, for example, [(3-hydroxypyridine-2-carbonyl]amino}acetic acid esters and [3-hydroxypyridine-2-carbonyl]amino}acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibitors or for treating conditions wherein prolyl hydroxylase inhibition is desired.

  公开了制备[(3-羟基吡啶-2-羰基)氨基]-烷酸的工艺，其衍生物包括 5-芳基取代的和 5-杂芳基取代的[(3-羟基吡啶-2-羰基)氨基}乙酸。进一步公开了制造[(3-羟基吡啶-2-羰基)氨基]乙酸原药的方法，例如[(3-羟基吡啶-2-羰基]氨基}乙酸酯和[3-羟基吡啶-2-羰基]氨基}乙酸酰胺。所公开的化合物可作为脯氨酰羟化酶抑制剂或用于治疗需要抑制脯氨酰羟化酶的病症。